Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 48

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Breast cancer in situ+1

Not recruiting

Study on Breast Cancer Prevention in High-Risk Women Using Low Dose Tamoxifen and Lifestyle Changes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tamoxifen Citrate
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on the Effects of Ribociclib and Endocrine Therapy for Patients with HR-Positive, HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Menopausal symptoms

Not recruiting

Study on the Effects of Estetrol Monohydrate on Hair Growth in Postmenopausal Women with Hair Loss

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Estetra

Infertility female

Not recruiting

Study on the Effects of Letrozole in Reducing Ovarian Volume in Women Undergoing Controlled Ovarian Stimulation for Egg Donation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · Healthy volunteers
  • Substances:Letrozole
  • Sponsor:Ivi Madrid S.L.

Breast cancer+2

Not recruiting

Study on Denosumab to Prevent Breast Cancer in Women with BRCA1 Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · Healthy volunteers
  • Substances:Denosumab
  • Sponsor:ANZ Breast Cancer Trials Group Limited

Infertility female

Not recruiting

Study on the Effects of Progesterone in Different Forms for Women with Infertility

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · Healthy volunteers
  • Substances:Progesterone
  • Sponsor:Ivi Valencia S.L.

Testosterone deficiency syndrome+1

Not recruiting

Study on How Elinzanetant Affects Dabigatran Etexilate in Healthy Volunteers with Vasomotor Symptoms

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Dabigatran Etexilate
  • Sponsor:Bayer AG

Prostate cancer

Not recruiting

Study on Sildenafil and Vacuum Erection Device Therapy for Men with Prostate Cancer Undergoing Nerve-Sparing Surgery

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Sildenafil
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Breast cancer+3

Not recruiting

Study of BT8009 for Patients with Advanced Breast Cancer with NECTIN4 Amplification

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ZELENECTIDE PEVEDOTIN
  • Sponsor:Bicycletx Limited

Hormone-refractory prostate cancer

Not recruiting

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Celgene Corp.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group

Triple negative breast cancer

Not recruiting

Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Stage I Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Medica Scientia Innovation Research S.L.

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.